Brii Biosciences Limited (HKG:2137)

Brii Biosciences Statistics

Total Valuation

HKG:2137 has a market cap or net worth of HKD 1.13 billion. The enterprise value is -1.20 billion.

Market Cap	1.13B
Enterprise Value	-1.20B

Important Dates

The next estimated earnings date is Friday, March 20, 2026.

Earnings Date	Mar 20, 2026
Ex-Dividend Date	n/a

Share Statistics

HKG:2137 has 721.53 million shares outstanding. The number of shares has decreased by -0.28% in one year.

Current Share Class	721.53M
Shares Outstanding	721.53M
Shares Change (YoY)	-0.28%
Shares Change (QoQ)	-0.99%
Owned by Insiders (%)	5.02%
Owned by Institutions (%)	5.22%
Float	594.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	35.70
PB Ratio	0.42
P/TBV Ratio	0.47
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	2.91
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	2.94

Financial Position

The company has a current ratio of 42.98, with a Debt / Equity ratio of 0.00.

Current Ratio	42.98
Quick Ratio	42.68
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-110.62

Financial Efficiency

Return on equity (ROE) is -14.42% and return on invested capital (ROIC) is -8.60%.

Return on Equity (ROE)	-14.42%
Return on Assets (ROA)	-8.42%
Return on Invested Capital (ROIC)	-8.60%
Return on Capital Employed (ROCE)	-14.88%
Weighted Average Cost of Capital (WACC)	11.79%
Revenue Per Employee	328,437
Profits Per Employee	-4.29M
Employee Count	96
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.20% in the last 52 weeks. The beta is 1.34, so HKG:2137's price volatility has been higher than the market average.

Beta (5Y)	1.34
52-Week Price Change	+32.20%
50-Day Moving Average	1.53
200-Day Moving Average	1.81
Relative Strength Index (RSI)	53.39
Average Volume (20 Days)	1,240,900

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HKG:2137 had revenue of HKD 31.53 million and -411.68 million in losses. Loss per share was -0.57.

Revenue	31.53M
Gross Profit	31.53M
Operating Income	-397.23M
Pretax Income	-414.20M
Net Income	-411.68M
EBITDA	-396.94M
EBIT	-397.23M
Loss Per Share	-0.57

Balance Sheet

The company has 2.27 billion in cash and 8.10 million in debt, with a net cash position of 2.27 billion or 3.14 per share.

Cash & Cash Equivalents	2.27B
Total Debt	8.10M
Net Cash	2.27B
Net Cash Per Share	3.14
Equity (Book Value)	2.67B
Book Value Per Share	3.79
Working Capital	2.24B

Cash Flow

In the last 12 months, operating cash flow was -403.77 million and capital expenditures -2.73 million, giving a free cash flow of -406.50 million.

Operating Cash Flow	-403.77M
Capital Expenditures	-2.73M
Free Cash Flow	-406.50M
FCF Per Share	-0.56

Margins

Gross Margin	100.00%
Operating Margin	-1,259.84%
Pretax Margin	-1,313.65%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

HKG:2137 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.28%
Shareholder Yield	0.28%
Earnings Yield	-36.57%
FCF Yield	-36.11%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HKG:2137 has an Altman Z-Score of 7.19 and a Piotroski F-Score of 2.

Altman Z-Score	7.19
Piotroski F-Score	2